EP Patent

EP3698776A1 — Tamper-resistant dosage form with immediate release and resistance against solvent extraction

Assigned to Gruenenthal GmbH · Expires 2020-08-26 · 6y expired

What this patent protects

The invention relates to a tamper-resistant pharmaceutical dosage form comprising a multitude of particles which comprise a pharmacologically active compound, preferably selected from opioids; a polyalkylene oxide having a weight average molecular weight within the range of from …

USPTO Abstract

The invention relates to a tamper-resistant pharmaceutical dosage form comprising a multitude of particles which comprise a pharmacologically active compound, preferably selected from opioids; a polyalkylene oxide having a weight average molecular weight within the range of from 200,000 g/mol to 2,000,000 g/mol, and a disintegrant; wherein the pharmacologically active compound is dispersed in a matrix comprising the polyalkylene oxide and the disintegrant; wherein the content of the disintegrant is more than 20 wt.-%, based on the total weight of the particles; wherein the content of the polyalkylene oxide is at least 25 wt.-%, based on the total weight of the particles; and wherein the dosage form provides under in vitro conditions immediate release of the pharmacologically active compound in accordance with Ph. Eur.

Drugs covered by this patent

Patent Metadata

Patent number
EP3698776A1
Jurisdiction
EP
Classification
Expires
2020-08-26
Drug substance claim
No
Drug product claim
No
Assignee
Gruenenthal GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.